Provided by Tiger Trade Technology Pte. Ltd.

Neuraxis, Inc.

4.36
+0.01000.23%
Volume:13.05K
Turnover:57.98K
Market Cap:46.45M
PE:-4.32
High:4.57
Open:4.35
Low:4.35
Close:4.35
52wk High:6.20
52wk Low:1.33
Shares:10.65M
Float Shares:7.67M
Volume Ratio:0.33
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0098
EPS(LYR):-1.2217
ROE:-3071.15%
ROA:-125.53%
PB:20.36
PE(LYR):-3.57

Loading ...

Neuraxis announces Category I CPT code for PENFS now in effect

TIPRANKS
·
Jan 08

NeurAxis Inc. to Present at Lytham Partners Healthcare Investor Summit

Reuters
·
Jan 08

NeurAxis Inc. Director Aharon Gil Reports Acquisition of Common Shares

Reuters
·
Dec 30, 2025

Neuraxis Is Maintained at Buy by Craig-Hallum

Dow Jones
·
Dec 23, 2025

NeurAxis Secures VA Federal Supply Schedule Contract for IB-Stim

Reuters
·
Dec 01, 2025

Neuraxis Inc: Co Expects Va Award to Support Sustained Commercial Momentum Entering 2026

THOMSON REUTERS
·
Dec 01, 2025

Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients With Functional Abdominal Pain

THOMSON REUTERS
·
Dec 01, 2025

Neuraxis announces new medical policy coverage in Michigan

TIPRANKS
·
Nov 12, 2025

NeurAxis, Inc. Earnings Call: Growth Amid Challenges

TIPRANKS
·
Nov 12, 2025

NeurAxis Inc. reports third quarter revenue up 22% to $811,000

Reuters
·
Nov 11, 2025

Press Release: NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

Dow Jones
·
Nov 11, 2025

Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate

Benzinga
·
Nov 11, 2025

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC)

TIPRANKS
·
Nov 10, 2025

NeurAxis Inc. to Release Third Quarter 2025 Results

Reuters
·
Nov 04, 2025

Neuraxis received FDA 510k clearance for PENFS technology

TIPRANKS
·
Oct 24, 2025

NeurAxis Wins FDA Clearance for First Adult Functional Dyspepsia Pain Device

Reuters
·
Oct 24, 2025

Neuraxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) With Associated Nausea Symptoms in the Adult Patient Population

THOMSON REUTERS
·
Oct 24, 2025

NeurAxis Inc. reports $0.8 million net sales and $2.1 million operating loss for Q3 2025

Reuters
·
Oct 24, 2025

Craig-Hallum Reaffirms Their Buy Rating on NeurAxis, Inc. (NRXS)

TIPRANKS
·
Sep 25, 2025

NeurAxis Inc. Announces $3.3 Million At-The-Market Offering Agreement with Craig-Hallum Capital

Reuters
·
Sep 02, 2025